ArticleScientific reports2018
The prognostic significance of heart-type fatty acid binding protein in patients with stable coronary heart disease.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Heart-Type Fatty Acid-Binding Protein as a Marker of Subclinical Cardiac Dysfunction and Cardiorenal Interaction in Autosomal Dominant Polycystic Kidney Disease.Life (Basel, Switzerland) · 2026Article
- Incremental Prognostic Value of Heart-Type Fatty Acid Binding Protein in Patients With Light Chain Cardiac Amyloidosis: A Prospective Cohort Study.Clinical and translational science · 2026Article
- Diagnostic and prognostic utility of heart-type fatty acid binding proteins in cardiovascular diseases and risk factors - an updated review of the literature.International journal of cardiology. Heart & vasculature · 2025Review
- Diagnostic Biomarkers for Risk Estimation of In-Hospital and Post-Discharge Cardiovascular Mortality in ST-Segment Elevation Myocardial Infarction (STEMI) Patients.Journal of clinical medicine · 2025Article
- Article
- H-FABP and Hs-cTnI Serum Concentrations Associate with the Development of Cardiovascular Events in Newly Diagnosed T2D, Pre-DM, and Normoglycemic Individuals.Vascular health and risk management · 2025Article
- Markers of cardiac injury in patients with liver cirrhosis.Croatian medical journal · 2023Review
- From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction.International journal of molecular sciences · 2022Review
- Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria.Current heart failure reports · 2022Review
- Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future.International journal of molecular sciences · 2022Review
- Cerebrospinal fluid levels of fatty acid-binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Prognostic indicators for the onset of ischaemic versus haemorrhagic stroke in stable coronary artery disease.Medicine · 2021Article
- [New cardiac biomarkers for early detection of myocardial infarction in cardiac surgery].Der Anaesthesist · 2021Review
- Heart-type fatty acid binding protein predicts cardiovascular events in patients with stable coronary artery disease: a prospective cohort study.Annals of translational medicine · 2020Article
- H-FABP: A beacon of hope for prediabetic heart disease.Journal of family medicine and primary care · 2020Article
- Potential impacts of high-sensitivity creatine kinase-MB on long-term clinical outcomes in patients with stable coronary heart disease.Scientific reports · 2020Article
- Heart-Type Fatty Acid-Binding Protein (H-FABP) and its Role as a Biomarker in Heart Failure: What Do We Know So Far?Journal of clinical medicine · 2020Review
- Association of Biomarker Level with Cardiovascular Events: Results of a 4-Year Follow-Up Study.Cardiology research and practice · 2020Article
- Biomarkers in heart failure: the past, current and future.Heart failure reviews · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the prognostic value of heart-type fatty acid binding protein (H-FABP) in patients with stable coronary heart disease (SCHD). A total of 1,071 patients with SCHD were prospectively enrolled in this Taiwan multicenter registry study, followed for 24 months. The cut-off value of H-FABP, 4.143 pg/mL, was determined using receiver operating characteristic curves. The primary cardiovascular (CV) outcome was composite CV events, defined as cardiovascular or cerebrovascular death, myocardial infarction (MI), stroke, angina related-hospitalization, PAOD-related hospitalization and heart failure. Secondary outcomes included CV or cerebrovascular death, nonfatal MI, nonfatal stroke, and acute heart failure-related hospitalization. We found that the high H-FABP group had more than a two-fold higher rate of primary CV outcomes than the low H-FABP group (32.36% vs. 15.78%, p < 0.001). Eleven patients (4.82%) of the high H-FABP group died during the 24 months of follow-up, compared to only one patient (0.12%) in the low H-FABP group. The acute heart failure-related hospitalization rate was also significantly higher in the high H-FABP group (3.5% vs. 0.95%, p < 0.005). The results remained significant after adjusting for baseline covariates. In conclusion, H-FABP was an independent predictor for CV outcomes in the patients with SCHD, mainly in CV death and acute heart failure-related hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.